Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Ryo, Ito"'
Autor:
Ryo Ito, Hanae Morio, Tomoyo Baba, Yasuyuki Sakaguchi, Naomi Wakayama, Ryuto Isogai, Yoshiyuki Yamaura, Takafumi Komori, Tomomi Furihata
Publikováno v:
Pharmaceutical Research. 39:1575-1586
In vitro human blood-brain barrier (BBB) models in combination with central nervous system-physiologically based pharmacokinetic (CNS-PBPK) modeling, hereafter referred to as the "BBB/PBPK" method, are expected to contribute to prediction of brain dr
Autor:
Tomomi Furihata, Yoshiyuki Yamaura, Ryo Ito, Kenta Umehara, Hidetaka Akita, Keita Kitamura, Hanae Morio, Takafumi Komori
Publikováno v:
Biologicalpharmaceutical bulletin. 44(7)
In vitro blood-brain barrier (BBB) models are essential research tools for use in developing brain-targeted drugs and understanding the physiological and pathophysiological functions of the BBB. To develop BBB models with better functionalities, thre
Publikováno v:
Biochemical and Biophysical Research Communications. 489:21-28
CYP11B2 is a key enzyme involved in the synthesis of the mineralocorticoid aldosterone. CYP11B2 expression in the adrenal glands is controlled by the renin-angiotensin system (RAS), and plays an important role in the maintenance of electrolyte metabo
Autor:
Mitsugi Ookawara, Koji Takeuchi, Yusuke Moritoh, Hitomi Ogino, Tomoki Yoshihara, Masanori Watanabe, Shin-ichi Abe, Yoshimasa Ishimura, Ryo Ito, Yoshiyuki Tsujihata, Hirohisa Miyashita, Yasufumi Miyamoto, Nobuhiro Nishigaki, Hikaru Ueno, Yukio Yamada
Publikováno v:
Diabetes. 68
GPR40/FFAR1 is a G-protein-coupled receptor expressed in pancreatic islets and enteroendocrine cells. SCO-267 is a novel full agonist of GPR40 being developed as a treatment for type 2 diabetes and obesity. The efficacy of SCO-267 was investigated in
Autor:
Hitomi Ogino, Tsuyoshi Maekawa, Masanori Watanabe, Mitsugi Ookawara, Koji Takeuchi, Yusuke Moritoh, Hirohisa Miyashita, Hikaru Ueno, Akihiro Kobayashi, Shin-ichi Abe, Nobuhiro Nishigaki, Tomoki Yoshihara, Yukio Yamada, Yoshiyuki Tsujihata, Ryo Ito, Yasufumi Miyamoto
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 370(2)
The GPR40/FFA1 receptor is a G-protein-coupled receptor expressed in the pancreatic islets and enteroendocrine cells. Here, we report the pharmacological profiles of (3S)-3-cyclopropyl-3-{2-[(1-{2-[(2,2-dimethylpropyl)(6-methylpyridin-2-yl)carbamoyl]
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 357:217-227
Sulfonylureas (SUs) are widely used insulin secretagogues, but they have adverse effects including hypoglycemia and secondary failure. Fasiglifam/TAK-875, a selective GPR40 agonist, enhances glucose-stimulated insulin secretion and improves hyperglyc
Autor:
Keita Kitamura, Shota Suzuki, Hanae Morio, Naohiko Anzai, Kan Chiba, Hidetaka Akita, Kenta Umehara, Ryo Ito, Yoshiro Saito, Mari Hashimoto, Tomomi Furihata, Kosuke Saito
Publikováno v:
Journal of Pharmacological Sciences, Vol 137, Iss 4, Pp 350-358 (2018)
Astrocytes have shown longstanding promise as therapeutic targets for various central nervous system diseases. To facilitate drug development targeting astrocytes, we have recently developed a new conditionally immortalized human astrocyte cell line,
Publikováno v:
British Journal of Pharmacology. 170:568-580
Background and Purpose TAK-875, a selective GPCR40/free fatty acid receptor 1 agonist, improves glycaemic control by increasing glucose-dependent insulin secretion. Metformin is a first-line drug for treatment of type 2 diabetes that improves periphe
Autor:
Masato Tashiro, Takeshi Kurata, Takato Odagiri, Ryo Ito, Shin-ichi Tamura, Tadaki Suzuki, Akira Ainai, Hideki Hasegawa, Elly van Riet
Publikováno v:
Human Vaccines & Immunotherapeutics
Haemagglutination inhibition (HI) and neutralization (NT) titers as well as haemagglutinin (HA) specific antibody responses were examined in 50 healthy adults aged between 22 and 69 y old after two intranasal administrations of an inactivated whole v
Autor:
Tsuneo Yasuma, Ryo Ito, Masami Suzuki, Koji Takeuchi, Ayako Harada, Yoshiyuki Tsujihata, Yu Momose, Nobuyuki Negoro
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 339:228-237
G protein-coupled receptor 40/free fatty acid receptor 1 (GPR40/FFA(1)) is highly expressed in pancreatic β cells and mediates free fatty acid-induced insulin secretion. This study examined the pharmacological effects and potential for avoidance of